Researchers found that a new gene therapy, VY1706, shows promise in reducing tau protein levels in the brain, which is linked to neurodegenerative diseases like Alzheimer’s. In a study involving non-human primates, a single intravenous dose of VY1706 led to a significant reduction of tau protein by up to 64% in key brain areas over three months. Importantly, the therapy was well tolerated, with no adverse effects reported at the highest doses tested.

This discovery could be particularly relevant for those concerned about cognitive decline as they age. High levels of tau protein are associated with conditions that impair memory and cognitive function. If VY1706 proves effective in humans, it could offer a new way to protect brain health and potentially slow down the progression of neurodegenerative diseases, benefiting older adults and those at risk.

Currently, VY1706 is in the early stages of development. The findings come from a toxicology study in non-human primates, which is a critical step before moving to human trials. The company plans to submit an application to the FDA in 2026, with hopes of starting human testing later that year, pending regulatory approval. While the results are promising, it’s important to note that more research is needed to confirm the therapy’s effectiveness and safety in humans.

For those interested in brain health, staying informed about advancements like VY1706 is essential. While waiting for these therapies to become available, maintaining a healthy lifestyle through regular exercise, a balanced diet, and mental stimulation can also support cognitive function as you age.

Source: longevity.technology